A61K 51/1048
The tumor cell determinant being a carcino embryonic antigen
Official title: {the tumor cell determinant being a carcino embryonic antigen}
A61K51/1048 (The tumor cell determinant being a carcino embryonic antigen) appears on 101 US grants and 92 published applications in this corpus.
Search patents in A61K- Granted patents
- 101
- Published applications
- 92
- Assignees
- 45
- Inventors
- 163
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 3 | 0 |
| 1983 | 0 | 0 |
| 1984 | 3 | 0 |
| 1985 | 0 | 0 |
| 1986 | 2 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 3 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 3 | 0 |
| 1997 | 5 | 0 |
| 1998 | 5 | 0 |
| 1999 | 1 | 0 |
| 2000 | 4 | 0 |
| 2001 | 0 | 1 |
| 2002 | 2 | 3 |
| 2003 | 1 | 4 |
| 2004 | 1 | 2 |
| 2005 | 1 | 3 |
| 2006 | 2 | 4 |
| 2007 | 2 | 3 |
| 2008 | 4 | 5 |
| 2009 | 4 | 7 |
| 2010 | 7 | 7 |
| 2011 | 9 | 7 |
| 2012 | 6 | 6 |
| 2013 | 4 | 5 |
| 2014 | 2 | 3 |
| 2015 | 1 | 3 |
| 2016 | 2 | 3 |
| 2017 | 2 | 0 |
| 2018 | 4 | 2 |
| 2019 | 0 | 3 |
| 2020 | 1 | 2 |
| 2021 | 0 | 1 |
| 2022 | 3 | 7 |
| 2023 | 3 | 4 |
| 2024 | 1 | 4 |
| 2025 | 1 | 2 |
| 2026 | 2 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Antibody conjugates and uses thereof6 Oct 2026US 12,753,242 B2GlycoNex Inc.
- Combination therapy for treating cancer25 Aug 2026US 12,714,759 B2City of Hope
- Anti-CEACAM6 antibodies and methods of use18 Feb 2025US 12,227,570 B2Agency for Science, Technology and Research
- NIR-conjugated tumor-specific antibodies and uses thereof31 Dec 2024US 12,178,887 B2City of Hope
- Anti-CEACAM6 antibodies and methods of use21 Nov 2023US 11,820,821 B2Agency for Science, Technology and Research
- Anti-ceacam5/6 dual-binding antibodies3 Sep 2026US 2026/0258125 A1Nona Biosciences (Suzhou) Co., Ltd.
- Human antibodies and uses thereof6 Nov 2025US 2025/0340633 A1Diatheva S.R.L.
- Anti-ceacam6 antibodies and methods of use17 Jul 2025US 2025/0230236 A1Agency for Science, Technology and Research
- Anti-ceacam6 antibodies and methods of use1 Aug 2024US 2024/0254221 A1Agency for Science, Technology and Research
- Combination therapy30 May 2024US 2024/0173442 A1Hoffmann-La Roche Inc.
Most cited
By later US patents
- Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers510US 4,331,647 A1982
- Tumor localization and therapy with labeled antibodies to cell surface antigens217US 4,444,744 A1984
- Preparation and use of immunoconjugates182US 5,443,953 AImmunomedics, Inc. · 1995
- Intraperative, intravascular and endoscopic tumor and lesion detection and therapy with monovalent antibody fragments180US 5,716,595 AImmunomedics, Inc. · 1998
- Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy173US 6,096,289 AImmunomedics, Inc. · 2000